CSIMarket
 
Annovis Bio inc   (ANVS)
Other Ticker:  
 
 
Price: $9.0900 $0.17 1.906%
Day's High: $9.4 Week Perf: 0.89 %
Day's Low: $ 8.90 30 Day Perf: -12.34 %
Volume (M): 120 52 Wk High: $ 23.89
Volume (M$): $ 1,086 52 Wk Avg: $11.84
Open: $8.90 52 Wk Low: $5.42



 Market Capitalization (Millions $) 82
 Shares Outstanding (Millions) 9
 Employees 812
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -37
 Cash Flow (TTM) (Millions $) -11
 Capital Exp. (TTM) (Millions $) 0

Annovis Bio Inc
Annovis Bio Inc. is a biopharmaceutical company that was founded in 2008 and has its headquarters in Berwyn, Pennsylvania. The company focuses on developing novel therapies for neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and other related disorders.

Annovis Bio Inc. utilizes an integrated platform technology to identify and develop small molecule drugs that can address the root causes of neurodegenerative diseases. The company's approach involves targeting multiple pathologies of these disorders, including protein misfolding, inflammation, oxidative stress, and impaired energy metabolism.

The company has developed two lead compounds, ANVS-401 and ANVS-411, which are designed to address critical targets in neurodegenerative diseases. ANVS-401 is a phosphodiesterase type 7 (PDE7) inhibitor that prevents the breakdown of cyclic adenosine monophosphate (cAMP), a molecule that plays an essential role in neuronal function. ANVS-411 is an inhibitor of both 11e-hydroxysteroid dehydrogenase type 1 (11e-HSD1) and 15-lipoxygenase (15-LO), enzymes that are involved in neuroinflammation and oxidative stress in the central nervous system.

Annovis Bio Inc. is also developing a diagnostic test called ANSnap, which is designed to detect early-stage neurodegeneration by measuring levels of toxic proteins in cerebrospinal fluid (CSF). This test has the potential to identify patients who are at risk of developing neurodegenerative diseases before significant damage to their brains has occurred.

Annovis Bio Inc. has collaborations with leading academic institutions, including the University of Pennsylvania, Thomas Jefferson University, and Harvard Medical School. The company has also received funding from the National Institutes of Health (NIH) and the Alzheimer's Drug Discovery Foundation (ADDF).

In summary, Annovis Bio Inc. is a biopharmaceutical company that focuses on developing novel therapies for neurodegenerative diseases. The company's integrated platform technology allows it to target multiple pathologies of these disorders. Annovis Bio Inc. has developed two lead compounds, ANVS-401 and ANVS-411, and is also developing a diagnostic test called ANSnap. The company has collaborations with leading academic institutions and has received funding from the NIH and ADDF.


   Company Address: 1055 Westlakes Drive, Suite 300 Berwyn 19312 PA
   Company Phone Number: 727-3913   Stock Exchange / Ticker: NYSE ANVS
   ANVS is expected to report next financial results on March 30, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Annovis Bio's Buntanetap Completes Phase II/III Study, Potential Breakthrough in Alzheimer's Treatment Imminent

Published Wed, Feb 14 2024 12:30 PM UTC

Annovis Bio, a clinical-stage drug platform company focused on developing innovative therapies for neurodegenerative diseases, has reported the completion of the last patient's final visit in the Phase II/III study of their lead candidate, buntanetap, for patients with mild to moderate Alzheimer's disease (AD). This significant milestone represents a major step forward in th...

Clinical Study

Annovis Bio Takes Extra Precautions to Ensure Accuracy and Reliability of Parkinson's Phase III Study Data

Published Wed, Jan 24 2024 1:00 PM UTC

Annovis Bio Delays Parkinson's Phase III Study Data Announcement for Improved Accuracy and ReliabilityMALVERN, Pa., Jan. 24, 2024 - Annovis Bio, Inc. (NYSE: ANVS), a renowned clinical-stage drug platform company specializing in the development of innovative therapies for neurodegenerative diseases, has recently announced a slight postponement in the release of Phase III stud...

Clinical Study

Annovis Bio's Buntanetap Achieves Remarkable Enrollment Success in Alzheimer's Disease Trial: A Game-Changing Breakthrough in Neurodegenerative Therapies

Published Mon, Nov 27 2023 12:30 PM UTC



Annovis Bio, a groundbreaking clinical-stage drug platform company focused on combating neurodegenerative diseases, has recently achieved a significant milestone in the development of its lead compound, buntanetap. According to an official statement released on November 27, 2023, the company announced the successful completion of patient enrollment for its Phase II...

Annovis Bio Inc

Annovis Bio Inc Reports Flat Revenue and Declining Operating Shortfall in Third Quarter of 2023

Annovis Bio Inc is a major player in the pharmaceutical industry, specializing in the development and production of innovative therapeutic drugs. However, recent financial reports indicate a concerning trend for the company.
During the fiscal period of July to September 2023, Annovis Bio Inc's revenue remained stagnant, much to the disappointment of investors. It was unexpected for the company to not witness any modifications in its revenue during this period. Moreover, the operating shortfall of Annovis Bio Inc was a significant concern, amounting to $-14.863271 million. This marked a deterioration from the third quarter of 2022, where the operating shortfall stood at $-7.674332 million.

Stock Issue News

Annovis Bio's Public Offering Signals Advancement in Neurodegenerative Disease Therapies.

Published Mon, Oct 30 2023 8:48 PM UTC

Annovis Bio Announces Public Offering as Neurodegenerative Disease Therapies Advance
BERWYN, Pa. - Annovis Bio, Inc. (NYSE: ANVS), a leading late-stage clinical drug platform company specializing in transformative therapies for neurodegenerative diseases such as Alzheimer's Disease and Parkinson's Disease, has recently unveiled its plans for a proposed underwritten publi...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com